MarketCapExport financials
So-Young International (SY)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
So-Young International Balance Sheet 2025-2011 | SY
Brief overview of So-Young International 's balance sheet structure
The balance sheet is assessed across five available annual reports spanning 2021 to 2025.
Assets finished at 2.6 billion CNY versus 3.3 billion CNY initially, losing -20.4%. The balance sheet contracted.
Liabilities expanded faster than the asset base, +20.6% versus -20.4%. Debt-service capacity deserves attention.
Internal capital represents 58.6% of the balance sheet, previously 75.6%. This is a strong capital position.
Net debt moved below zero to -158.3 million CNY, reflecting surplus cash over debt.
The balance sheet includes a negative accumulated result of -1.2 billion CNY. It should be assessed alongside historical profits and capital distributions.
Balance sheet takeaway
The balance sheet gives no single signal for So-Young International : some indicators are sound, while leverage or capitalization needs attention.
Annual Balance Sheet So-Young International
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-158 M | -418 M | -310 M | -623 M | - | - | - | -563 M | -441 M | - | - | - | - | - | - |
Long Term Debt |
183 M | 125 M | 86.2 M | 21 M | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
76.5 M | 44.9 M | 29.7 M | 50.3 M | - | 39.5 M | 37.8 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
197 M | 146 M | 113 M | 52 M | 101 M | 102 M | 121 M | - | 594 M | - | - | - | - | - | - |
Total Current Liabilities |
784 M | 630 M | 540 M | 538 M | 712 M | 571 M | 467 M | 302 M | - | - | - | - | - | - | - |
Total Liabilities |
981 M | 776 M | 653 M | 590 M | 813 M | 672 M | 587 M | 302 M | 735 M | - | - | - | - | - | - |
Deferred Revenue |
65.9 M | 76.6 M | 103 M | 110 M | - | 135 M | - | - | 57.2 M | - | - | - | - | - | - |
Retained Earnings |
-1.17 B | -926 M | -330 M | -347 M | -272 M | -254 M | -259 M | -394 M | -169 M | - | - | - | - | - | - |
Total Assets |
2.65 B | 2.74 B | 3.21 B | 3.2 B | 3.33 B | 3.29 B | 3.23 B | 1.34 B | 568 M | - | - | - | - | - | - |
Cash and Cash Equivalents |
418 M | 588 M | 426 M | 694 M | - | 1.13 B | 885 M | 563 M | 441 M | - | - | - | - | - | - |
Book Value |
1.67 B | 1.96 B | 2.56 B | 2.61 B | 2.52 B | 2.62 B | 2.64 B | 1.04 B | -167 M | - | - | - | - | - | - |
Total Shareholders Equity |
1.55 B | 1.84 B | 2.44 B | 2.5 B | 2.52 B | 2.6 B | 2.64 B | -358 M | -167 M | - | - | - | - | - | - |
All numbers in CNY currency
Quarterly Balance Sheet So-Young International
| 2025-Q4 | 2024-Q4 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
183 M | 125 M | 86.2 M | - | - | - | - | 62.4 M | - | - | - | 93 M | - | - | - | 121 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
197 M | 146 M | 113 M | - | - | - | - | 101 M | - | - | - | 102 M | - | - | - | 121 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
981 M | 776 M | 653 M | - | - | - | - | 813 M | - | - | - | 672 M | - | - | - | 587 M | - | - | - | 302 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
65.9 M | 76.6 M | 103 M | - | - | - | - | 139 M | - | - | - | 135 M | - | - | - | 93.7 M | - | - | - | 117 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.17 B | -926 M | -330 M | - | - | - | - | -272 M | - | - | - | -254 M | - | - | - | -259 M | - | - | - | -394 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
2.65 B | 2.74 B | 3.21 B | - | - | - | - | 3.33 B | - | - | - | 3.29 B | - | - | - | 3.23 B | - | - | - | 1.34 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
418 M | 588 M | 426 M | - | - | - | - | 1.33 B | - | - | - | 1.13 B | - | - | - | 885 M | - | - | - | 563 M | - | - | - | 441 M | - | - | - | 18.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
1.67 B | 1.96 B | 2.56 B | - | - | - | - | 2.52 B | - | - | - | 2.62 B | - | - | - | 2.64 B | - | - | - | 1.04 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
1.55 B | 1.84 B | 2.44 B | - | - | - | - | 2.45 B | - | - | - | 2.6 B | - | - | - | 2.64 B | - | - | - | -358 M | - | - | - | -167 M | - | - | - | -156 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CNY currency
Balance Sheet is a fundamental financial report of So-Young International , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Health information services
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
GoodRx Holdings
GDRX
|
$ 3.53 | 4.13 % | $ 1.26 B |  USA |
 |
Health Catalyst
HCAT
|
$ 1.77 | 3.82 % | $ 124 M | USA |
 |
HealthEquity
HQY
|
$ 95.89 | 0.25 % | $ 8.26 B | USA |
 |
HealthStream
HSTM
|
$ 29.6 | 1.68 % | $ 889 M | USA |
 |
Omnicell
OMCL
|
$ 33.57 | 2.38 % | $ 1.54 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 7.72 | 5.9 % | $ 143 M | USA |
 |
Progyny
PGNY
|
$ 27.73 | 1.39 % | $ 2.36 B | USA |
 |
Phreesia
PHR
|
$ 10.34 | 0.29 % | $ 618 M | USA |
 |
Schrödinger
SDGR
|
$ 20.55 | 8.02 % | $ 1.51 B | USA |
 |
Teladoc Health
TDOC
|
$ 6.54 | 6.09 % | $ 1.15 B | USA |
 |
10x Genomics
TXG
|
$ 69.83 | 1.81 % | $ 8.71 B | USA |
 |
Veeva Systems
VEEV
|
$ 265.27 | 1.09 % | $ 43.4 B | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
American Well Corporation
AMWL
|
$ 13.92 | 6.58 % | $ 223 M | USA |
 |
Evolent Health
EVH
|
$ 4.06 | 0.48 % | $ 464 M | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
Zhongchao
ZCMD
|
$ 0.75 | 4.0 % | $ 2.56 M |  China |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
- | - | $ 7.71 M | USA |